Incyte (INCY)
(Delayed Data from NSDQ)
$75.59 USD
+0.70 (0.93%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $75.60 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Incyte Corporation's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
INCY 75.59 +0.70(0.93%)
Will INCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Incyte (INCY) is a Top Value Stock for the Long-Term
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for INCY
Incyte (INCY) Leads Healthcare Gains Despite Market Dip
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News